Detalhe da pesquisa
1.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Ann Hematol
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38438627
2.
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.
Ann Hematol
; 102(2): 349-358, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564535
3.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
Blood
; 135(5): 381-386, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869407
4.
Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients.
Eur J Haematol
; 108(2): 154-162, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34719056
5.
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
Blood
; 133(8): 840-851, 2019 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30563875
6.
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Hematol Oncol
; 39(4): 558-566, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34224180
7.
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms.
Ann Hematol
; 100(8): 2015-2022, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216197
8.
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.
Ann Hematol
; 100(11): 2707-2716, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34462786
9.
The management, outcome, and postpartum disease course of 41 pregnancies in 20 women with polycythemia vera.
Eur J Haematol
; 107(1): 122-128, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33763907
10.
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Br J Haematol
; 189(5): 888-903, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32017044
11.
Second cancers in MPN: Survival analysis from an international study.
Am J Hematol
; 95(3): 295-301, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31816122
12.
Thromboembolic events in polycythemia vera.
Ann Hematol
; 98(5): 1071-1082, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30848334
13.
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.
Ann Hematol
; 98(1): 93-100, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30155552
14.
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.
Ann Hematol
; 98(4): 897-907, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30610279
15.
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
N Engl J Med
; 372(5): 426-35, 2015 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25629741
16.
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.
Haematologica
; 103(1): 51-60, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29079600
17.
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.
Ann Hematol
; 97(9): 1591-1600, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29804268
18.
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
Ann Hematol
; 97(4): 617-627, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29396713
19.
Recommendations for the diagnosis and treatment of patients with polycythaemia vera.
Eur J Haematol
; 2018 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30058088
20.
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Lancet Oncol
; 18(1): 88-99, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27916398